It has been shown that %f-PSA is decreased in men with prostate cancer. The aim of this study was to analyse the impact of %f-PSA in men with t-PSA between 0.5 ± 3 ng/ml compared to men with t-PSA 3 ± 4 ng/ml who all underwent TRUS guided systematic sextant biopsies.
Method
One hundred and eighty-two men with t-PSA`3 ng/ml and 78 men with t-PSA 3 ±`4 ng/ml underwent TRUS guided systematic sextant biopsies (TRUS-6BX). Indication for biopsies were suspicious DRE, suspicious TRUS or PSA-velocity b 0.75 ng/ml/y. Before prostate manipulation, blood samples were taken for t-PSA and f-PSA with Abbott Axsym-Assay (Abbott Park, II, USA). T-PSA concentration was in the range 0 ±`1 ng/ml in 59 men, 1 ±`2 ng/ml in 58 men, 2 ±`3 ng/ml in 65 men and 3 ± 4 ng/ml in 78 men.
Results
Prostate cancer (PCa) was found in 44 men (group I) (PSA 0 ±`1 ng/ml, n 1: PSA 1 ±`2 ng/ml, n 8; PSA 2 ± 3 ng/ml, n 15; PSA 3 ± 4 ng/ml, n 20). Mean %f-PSA was 20.92% (range 5.0% ± 57%; s.d.: 10.5%) with a mean t-PSA of 2.78 ng/ml. Only men with PSA 3 ±`4 ng/ml had lower %f-PSA ratios (17.9% f-PSA) compared to men with t-PSA`3 ng/ml (23.94% f-PSA). In 216 men without biopsy proven PCa (group II) mean %f-PSA was 24.61% (range 4.3 ± 66%; s.d.: 10.8) with a mean t-PSA of 2.04 ng/ml (P-value 0.31, Mann ± Whitney U-test).
Conclusion
These data indicate that in men with PSA`3 ng/ml %f-PSA measured by the Abbott Axsym-Assay does not increase early PCa detection.
